Cidara Therapeutics Inc , a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections announced today the completion of a 42 million private Series B financing Participants in the financing comprise a syndicate of healthcare-dedicated institutional investors and include both new and existing investors in Cidara
We appreciate the support and confidence demonstrated by our new and existing investors in this round said Jeff Stein Ph D , chief executive officer of Cidara Proceeds from the financing will enable us to accelerate the development of our echinocandin antifungal programs biafungin and topifungin as well as our immunotherapy platform Cloudbreak which we believe may represent a fundamentally new approach to the treatment of infectious diseases ‘
About Cidara Therapeutics
Cidara is a privately held biotechnology company focused on the discovery development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies Cidara’s initial portfolio is comprised of long-acting echinocandin antifungal product candidates biafungin and topifungin for the treatment of serious fungal infections In addition Cidara has developed a proprietary immunotherapy platform CloudbreakTM designed to create antifungals antibacterials and antivirals that direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease Cidara is headquartered in San Diego California
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Cidara%20Therapeutics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
